A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer : clinical results and biomarker analysis of GeparNuevo study

Loibl, S.; Untch, M.; Burchardi, N.; Huober, J.; Sinn, B., V; Blohmer, J-U; Grischke, E-M; Furlanetto, J.; Tesch, H.; Hanusch, C.; Engels, K.; Rezai, M.; Jackisch, C.; Schmitt, W. D.; von Minckwitz, G.; Thomalla, J.; Kuemmel, S.; Rautenberg, B.; Fasching, P. A.; Weber, K.; Rhiem, K.; Denkert, C.; Schneeweiss, A.

Publication services
→
Universitätsbibliographie
→
4 Medizinische Fakultät
→
View Item

« back

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer : clinical results and biomarker analysis of GeparNuevo study

Author:

Loibl, S.; Untch, M.; Burchardi, N.; Huober, J.; Sinn, B., V; Blohmer, J-U; Grischke, E-M; Furlanetto, J.; Tesch, H.; Hanusch, C.; Engels, K.; Rezai, M.; Jackisch, C.; Schmitt, W. D.; von Minckwitz, G.; Thomalla, J.; Kuemmel, S.; Rautenberg, B.; Fasching, P. A.; Weber, K.; Rhiem, K.; Denkert, C.; Schneeweiss, A.

Tübinger Autor(en):

Grischke, Eva-Maria

Published in:

Annals of Oncology (2019), Bd. 30, H. 8, S. 1279-1288

Verlagsangabe:

Oxford Univ Press

Language:

English

Full text:

http://dx.doi.org/10.1093/annonc/mdz158

ISSN:

1569-8041